Please login to the form below

squamous cell cancer

This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.

Keytruda adds another NSCLC approval in Europe

In combination with chemotherapy, the anti-PD-1 therapy has been approved as a first-line medicine for those with metastatic squamous non-small cell lung cancer (NSCLC). ... Keytruda provides a foundation for the treatment of lung cancer in Europe, and

Latest news

Celgene’s Abraxane fails pancreatic cancer trial

Celgene picked up the first of these last October when Abraxane was cleared alongside Merck &Co/MSD’s Keytruda (pembrolizumab) for frontline metastatic squamous non-small cell lung cancer. ... for a breast cancer indication – and in September, the
Tecentriq combo gains European NSCLC approval

In combination with chemotherapy and Roche’s older cancer treatment Avastin, Tecentriq can now treat those with EGFR mutant, or ALK-positive metastatic non-squamous non-small cell lung cancer (NSCLC). ... Today’s announcement makes the combination of
Ocrevus helps Roche shrug off biosimilars in 2018

cancer therapy Herceptin (trastuzumab) offset by gains of 14% in the US and 10% elsewhere. ... for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).
NICE lung cancer backing for Keytruda is biggest expansion yet

cell lung cancer (NSCLC) patients in combination with chemotherapy for up to two years. ... The availability of combination therapy is a huge leap forward in improving the prognosis of patients with non-squamous non-small cell lung cancer.”.
Roche’s Tecentriq misses survival mark in frontline NSCLC

Keytruda proving hard to beat. Roche's hopes of challenging Merck &Co for a slice of the lucrative first-line non-small cell lung cancer (NSCLC) immunotherapy market have been set ... This is our third phase 3 trial in non-squamous non-small cell lung

More from news
Approximately 0 fully matching, plus 51 partially matching documents found.

Latest Intelligence

Immuno-oncology in 2019: the rapid evolution continues

It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of
Chinese biotech’s global ambitions

has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BIND Therapeutics appoints Andrew Hirsch as permanent CEO

Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Therapy Watch expands oncology and IBD portfolios

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.